Typo: It is hard “NOT” to believe that with an arrangement such as this (no brand V only GV covered) that a large percentage of those scripts are for the CVD indication and are clearly infringement on valid patents.
RMB, That is why the suit is important. It's also why Hikma is tying itself in knots to keep it out of the court. A deal like this shows both intent and action. It's also the way every generic company is exploiting their skinny label approval. Until a court set's precedent it will continue. GSK v Teva opened the door that Amarin is walking through. The advertising error that Hikma made has the potential to end generic abuse of the skinny label. Sleven,
Market Data 
Markets 
AI
